Topics
Diffuse midline glioma | Treatment | Targeted therapy | Bevacizumab
Home > Publications > Topics > Diffuse midline glioma > Treatment > Targeted therapy > Bevacizumab
Nakayasu S, Tanji M, Uto M, Takeuchi Y, Makino Y, Yamamoto Hattori
E, Terada Y, Sano N, Mineharu Y, Mizowaki T, Arakawa
Y.
Hypofractionated radiotherapy
combined with bevacizumab plus low-dose ifosfamide, carboplatin,
and etoposide as second-line chemoradiotherapy for progressing
spinal diffuse midline glioma, H3K27-altered: illustrative case.
J
Neurosurg Case Lessons. 2024 Aug 12;8(7):CASE2464. doi:
10.3171/CASE2464. PMID:
39133948. Case report. ˍ